Gypenoside L

Gypenoside L at a Glance

Gypenoside L is one of the dammarane-type triterpenoid saponins of jiaogulan (Gynostemma pentaphyllum), the vining herb widely sold as “southern ginseng.” It belongs to the protopanaxadiol branch of the dammarane family — the same skeleton that underpins ginseng’s ginsenosides — which is why jiaogulan and ginseng share part of their chemistry ^{10Reference 10Razmovski-Naumovski V et al. · 2005ReviewChemistry and pharmacology of Gynostemma pentaphyllum — reviewView study →}.

Two honesty notes frame everything below. First, “gypenosides” are almost always studied as a mixture, not as single molecules; jiaogulan’s ~200-plus saponins vary so much between plants that no individual gypenoside is reliably standardised ^{9Reference 9Nguyen NH et al. · 2021ReviewTriterpenoids from the genus Gynostemma: chemistry and pharmacological activities — reviewView study →}. Isolated gypenoside-L-specific data is therefore scarce, and where it exists it is overwhelmingly in-vitro cancer-cell work ^{1,2,3,4,5,6Reference 1Ma J et al. · 2019In vitroGypenoside L inhibits proliferation of liver and esophageal cancer cells by inducing senescence — in vitroView study →Reference 2Zheng K et al. · 2016In vitroGypenoside L, isolated from Gynostemma pentaphyllum, induces cytoplasmic vacuolation death in hepatocellular carcinoma cells through reactive-oxygen-species-mediated unfolded protein response — in vitroView study →Reference 3Liao C et al. · 2016In vitroGypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca²⁺ release — in vitroView study →Reference 4Xiao MY et al. · 2024In vitroGypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response — in vitroView study →Reference 5Liu H et al. · 2022In vitroGypenoside L and gypenoside LI inhibit proliferation in renal cell carcinoma via regulation of the MAPK and arachidonic acid metabolism pathways — in vitro + xenograftView study →Reference 6Wang TX et al. · 2018In vitroBioassay-guided isolation and identification of anticancer and antioxidant compounds from Gynostemma pentaphyllum (Thunb.) Makino — in vitroView study →}. Second, the compound’s clearest human-relevant signals — fatigue, exercise performance, liver support — come from whole jiaogulan extract, where gypenoside L is one saponin among many, not from the pure compound ^{7,8,13Reference 7Ahn Y et al. · 2023RCTEffects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: a double-blind, placebo-controlled, randomized trialView study →Reference 8Nayyar D et al. · 2023RCTGynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK in healthy males — randomized human trialView study →Reference 13Chen JC et al. · 2000AnimalTherapeutic effect of gypenoside on chronic liver injury and fibrosis induced by CCl₄ in rats — animal modelView study →}.

The single most consistent isolated-molecule finding is that gypenoside L pushes cancer cells into senescence or into non-apoptotic forms of death in the dish — a laboratory anticancer signal, not a demonstrated human therapy.

Gypenosides & “Southern Ginseng”

Jiaogulan earns its “southern ginseng” nickname from chemistry, not folklore. Its active saponins, the gypenosides, are dammarane-type triterpenoids built on the same protopanaxadiol/protopanaxatriol skeletons as ginseng’s ginsenosides — and a meaningful slice of them are literally the same molecules. Around a quarter of jiaogulan’s total saponin pool is shared ginsenosides (including ginsenoside Rb1’s relatives Rb3, Rd and F2), which is the structural basis for jiaogulan being pitched as a cheaper, faster-growing source of ginseng-like saponins ^{10Reference 10Razmovski-Naumovski V et al. · 2005ReviewChemistry and pharmacology of Gynostemma pentaphyllum — reviewView study →}. The remaining gypenosides are close structural cousins rather than exact copies.

Two cautions keep this from being a simple “jiaogulan = ginseng” story:

• The mixture problem. Total gypenosides sit at roughly 2.4% of the dried plant, but the individual profile — how much gypenoside L versus A, IX, LVI, or shared Rb1 — swings widely with cultivar, ploidy and processing, and no single gypenoside is a dependable marker across products ^{9,10Reference 9Nguyen NH et al. · 2021ReviewTriterpenoids from the genus Gynostemma: chemistry and pharmacological activities — reviewView study →Reference 10Razmovski-Naumovski V et al. · 2005ReviewChemistry and pharmacology of Gynostemma pentaphyllum — reviewView study →}. A “gypenoside-L-standardised” extract is a formulation choice, not a natural constant.
• Isolate-L data is thin. Where gypenoside L has been studied as the isolate, it is almost entirely cell-culture anticancer work — its own distinctive signal is senescence induction and non-apoptotic cell death, not the tonic/adaptogenic profile the ginsenosides are known for ^{1,2,3Reference 1Ma J et al. · 2019In vitroGypenoside L inhibits proliferation of liver and esophageal cancer cells by inducing senescence — in vitroView study →Reference 2Zheng K et al. · 2016In vitroGypenoside L, isolated from Gynostemma pentaphyllum, induces cytoplasmic vacuolation death in hepatocellular carcinoma cells through reactive-oxygen-species-mediated unfolded protein response — in vitroView study →Reference 3Liao C et al. · 2016In vitroGypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca²⁺ release — in vitroView study →}. The senescence and hepatocellular-carcinoma findings are the reason gypenoside L is singled out at all; they are also entirely preclinical.

So the accurate framing is: jiaogulan is a legitimate dammarane-saponin source that overlaps with ginseng, gypenoside L is one of its individually-named members, and what we actually know about this molecule is a laboratory anticancer story — separate from the whole-extract human data on fatigue and metabolism.

What It's Used For

Gypenoside L’s evidence splits sharply by what was tested. The isolated molecule appears almost exclusively in in-vitro oncology; the human signals ride on whole jiaogulan extract that merely contains or is standardised to it.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume, tempered for isolate-vs-plant match and bioavailability. A beta, not a validated metric. Note the split: the best-studied application (anticancer) is isolate-but-in-vitro, while the applications with human data rest on whole extract, not gypenoside L itself.

01Anticancer — Senescence & Cell DeathShaky36%Isolated gypenoside L across HCC, esophageal, renal, lung, breast lines; in vitro (+ one xenograft); no human data ^{1,2,3,4,5,6Reference 1Ma J et al. · 2019In vitroGypenoside L inhibits proliferation of liver and esophageal cancer cells by inducing senescence — in vitroView study →Reference 2Zheng K et al. · 2016In vitroGypenoside L, isolated from Gynostemma pentaphyllum, induces cytoplasmic vacuolation death in hepatocellular carcinoma cells through reactive-oxygen-species-mediated unfolded protein response — in vitroView study →Reference 3Liao C et al. · 2016In vitroGypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca²⁺ release — in vitroView study →Reference 4Xiao MY et al. · 2024In vitroGypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response — in vitroView study →Reference 5Liu H et al. · 2022In vitroGypenoside L and gypenoside LI inhibit proliferation in renal cell carcinoma via regulation of the MAPK and arachidonic acid metabolism pathways — in vitro + xenograftView study →Reference 6Wang TX et al. · 2018In vitroBioassay-guided isolation and identification of anticancer and antioxidant compounds from Gynostemma pentaphyllum (Thunb.) Makino — in vitroView study →}

02Fatigue & Exercise PerformanceShaky30%Two human RCTs — but of whole jiaogulan extract containing/standardised to Gyp-L, not the isolate ^{7,8Reference 7Ahn Y et al. · 2023RCTEffects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: a double-blind, placebo-controlled, randomized trialView study →Reference 8Nayyar D et al. · 2023RCTGynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK in healthy males — randomized human trialView study →}

03Hepatoprotection & Metabolic (Class)Shaky18%Total-gypenoside mixture in rodents (CCl₄ liver injury, AMPK); not isolate-L specific ^{8,9,13Reference 8Nayyar D et al. · 2023RCTGynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK in healthy males — randomized human trialView study →Reference 9Nguyen NH et al. · 2021ReviewTriterpenoids from the genus Gynostemma: chemistry and pharmacological activities — reviewView study →Reference 13Chen JC et al. · 2000AnimalTherapeutic effect of gypenoside on chronic liver injury and fibrosis induced by CCl₄ in rats — animal modelView study →}

Mechanisms

The load-bearing point: the isolate mechanisms (senescence, ROS-UPR, cholesterol-axis) are all cell-culture anticancer routes, while the whole-extract mechanisms (AMPK, eNOS) carry the human benefits — two different bodies of evidence that should not be merged.

Pharmacokinetics

There is no published human pharmacokinetics for isolated gypenoside L, and this is the load-bearing caveat under the in-vitro anticancer data. As a large, glycosylated protopanaxadiol-type dammarane saponin, it belongs to a class whose defining pharmacokinetic feature is poor oral absorption: low membrane permeability and gut-wall handling severely limit the bioavailability of these saponins, and the aglycone/deglycosylated forms are more absorbable than the intact glycosides ^{11Reference 11Wang M et al. · 2020ReviewDammarane-type leads panaxadiol and protopanaxadiol for drug discovery: biological activity and structural modification — reviewView study →}. What little Gynostemma-specific pharmacokinetic work exists was done on other gypenosides (LVI and XLVI) and their protopanaxadiol metabolites in rat plasma, not on gypenoside L ^{12Reference 12Zhang L et al. · 2015AnimalSimultaneous determination of gypenoside LVI, gypenoside XLVI, 2α-OH-protopanaxadiol and their two metabolites in rat plasma by LC-MS/MS and its application to pharmacokinetic studies — ratView study →}. By analogy with the closely related ginsenosides, intact oral saponin likely reaches tissue in only small amounts, with gut-microbial deglycosylation shaping the actual exposure — meaning the micromolar concentrations used in the cancer-cell studies may not be achievable from an oral dose.

Clinical Trials

There are no clinical trials of isolated gypenoside L. The human evidence attached to the name is for whole jiaogulan extract — a gypenoside-L-standardised extract for fatigue/exercise ^{7Reference 7Ahn Y et al. · 2023RCTEffects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: a double-blind, placebo-controlled, randomized trialView study →} and a jiaogulan extract for exercise performance and AMPK ^{8Reference 8Nayyar D et al. · 2023RCTGynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK in healthy males — randomized human trialView study →} — where the isolate’s individual contribution is unknown.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule is a clean case of the two literatures pointing in different directions. The isolated-compound evidence is real but narrow: reproducible in-vitro anticancer activity — senescence, ROS-UPR, autophagy blockade, cholesterol-axis suppression — across liver, esophageal, renal, lung and breast lines, with a single renal xenograft ^{1,2,3,4,5,6Reference 1Ma J et al. · 2019In vitroGypenoside L inhibits proliferation of liver and esophageal cancer cells by inducing senescence — in vitroView study →Reference 2Zheng K et al. · 2016In vitroGypenoside L, isolated from Gynostemma pentaphyllum, induces cytoplasmic vacuolation death in hepatocellular carcinoma cells through reactive-oxygen-species-mediated unfolded protein response — in vitroView study →Reference 3Liao C et al. · 2016In vitroGypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca²⁺ release — in vitroView study →Reference 4Xiao MY et al. · 2024In vitroGypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response — in vitroView study →Reference 5Liu H et al. · 2022In vitroGypenoside L and gypenoside LI inhibit proliferation in renal cell carcinoma via regulation of the MAPK and arachidonic acid metabolism pathways — in vitro + xenograftView study →Reference 6Wang TX et al. · 2018In vitroBioassay-guided isolation and identification of anticancer and antioxidant compounds from Gynostemma pentaphyllum (Thunb.) Makino — in vitroView study →}. The whole-plant evidence is where the human data lives: randomised trials of jiaogulan extract for fatigue, exercise capacity and AMPK-linked metabolism ^{7,8Reference 7Ahn Y et al. · 2023RCTEffects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: a double-blind, placebo-controlled, randomized trialView study →Reference 8Nayyar D et al. · 2023RCTGynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK in healthy males — randomized human trialView study →}, plus rodent hepatoprotection for the total-gypenoside mixture ^{13Reference 13Chen JC et al. · 2000AnimalTherapeutic effect of gypenoside on chronic liver injury and fibrosis induced by CCl₄ in rats — animal modelView study →}. Because jiaogulan is chemically a mixture no product standardises to a single member ^{9Reference 9Nguyen NH et al. · 2021ReviewTriterpenoids from the genus Gynostemma: chemistry and pharmacological activities — reviewView study →}, even the “gypenoside-L-standardised” trial ^{7Reference 7Ahn Y et al. · 2023RCTEffects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: a double-blind, placebo-controlled, randomized trialView study →} tests an extract, not the molecule. The transferability caveat therefore runs both ways: the isolate’s anticancer mechanisms have never been shown in people, and the extract’s human benefits cannot be pinned on gypenoside L specifically.

Prevalence in Nature

Gypenoside L occurs in jiaogulan (Gynostemma pentaphyllum), chiefly the leaf, as one member of a saponin family exceeding 200 structures; related Gynostemma species (e.g. G. longipes) carry overlapping dammarane saponins ^{9Reference 9Nguyen NH et al. · 2021ReviewTriterpenoids from the genus Gynostemma: chemistry and pharmacological activities — reviewView study →}. Total gypenoside saponins amount to roughly 2.4% of the dried plant, of which about a quarter are ginsenosides shared with Panax ginseng — the chemical basis of the “southern ginseng” label ^{10Reference 10Razmovski-Naumovski V et al. · 2005ReviewChemistry and pharmacology of Gynostemma pentaphyllum — reviewView study →}. The individual abundance of gypenoside L is not reliably quantified or standardised: it varies with cultivar, ploidy level and how the leaf is processed, and no single gypenoside serves as a dependable content marker across products ^{9,10Reference 9Nguyen NH et al. · 2021ReviewTriterpenoids from the genus Gynostemma: chemistry and pharmacological activities — reviewView study →Reference 10Razmovski-Naumovski V et al. · 2005ReviewChemistry and pharmacology of Gynostemma pentaphyllum — reviewView study →}. Unlike the ginsenosides, which are essentially confined to Panax, the gypenosides are characteristic of the Gynostemma genus.

Discovery & Synthesis

The gypenoside saponins were first catalogued in the early 1980s, when Takemoto and colleagues isolated and named gypenosides I–XIV from Gynostemma pentaphyllum (alongside the already-known ginsenosides Rb1, Rb3, Rd and F2 they found in the same plant), published in 1983 ^{14Reference 14Takemoto T et al. · 1983Studies on the constituents of Gynostemma pentaphyllum MakinoView study →}. The numbering was extended in subsequent studies well past fifty members; gypenoside L (Roman numeral 50) belongs to that later series, and a discrete first-isolation record for it specifically is not well documented. There is no reported total synthesis: like the ginsenosides, gypenoside L is obtained by extraction and chromatographic fractionation from jiaogulan leaf, typically by bioassay-guided isolation ^{6Reference 6Wang TX et al. · 2018In vitroBioassay-guided isolation and identification of anticancer and antioxidant compounds from Gynostemma pentaphyllum (Thunb.) Makino — in vitroView study →}, rather than by chemical manufacture. No commercial isolate is produced at scale; what reaches people is whole or partially-purified jiaogulan extract.

Patents: not yet researched.

Toxicity & Safety

Gypenoside L carries a low toxicity flag, in line with the broadly favourable safety record of jiaogulan and the dammarane saponins generally — but this is a class inference and a whole-extract observation, not a characterised safety package for the isolated molecule. No dedicated repeat-dose, genotoxicity or reproductive-toxicity dataset exists for pure gypenoside L, and its cytotoxicity to cancer cells in vitro says nothing about systemic safety at achievable oral exposures (which are limited by poor absorption anyway ^{11Reference 11Wang M et al. · 2020ReviewDammarane-type leads panaxadiol and protopanaxadiol for drug discovery: biological activity and structural modification — reviewView study →}).

Safety at a Glance

✅ Low / no toxicity

• Low apparent toxicity in context. Jiaogulan and its dammarane saponins have a generally benign safety record at dietary/supplemental extract doses.
• Isolate is uncharacterised. No repeat-dose, genotoxicity, reproductive or human safety data exist for pure gypenoside L; its profile is inferred from the plant and the saponin class.
• Preparation matters. Whole-leaf tea, standardised extracts, and “gypenoside-L-standardised” products are not interchangeable — human trial results attach to specific extracts, not to the isolate ^{7,9Reference 7Ahn Y et al. · 2023RCTEffects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: a double-blind, placebo-controlled, randomized trialView study →Reference 9Nguyen NH et al. · 2021ReviewTriterpenoids from the genus Gynostemma: chemistry and pharmacological activities — reviewView study →}.
• Interactions not formally studied. No enzyme/transporter interaction work exists for isolated gypenoside L; the AMPK/metabolic activity of jiaogulan extract ^{8Reference 8Nayyar D et al. · 2023RCTGynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK in healthy males — randomized human trialView study →} is a theoretical reason for caution alongside glucose-lowering therapy, extrapolated from the plant, not the molecule.

Pregnancy and lactation are decided on the herb or product where intake actually happens (see jiaogulan), not on this molecule page; no isolate-specific reproductive data exist to add here.

Dosage

There is no established human dose of isolated gypenoside L — it is a research compound, not a standardised supplement. The human trials that name it dosed whole jiaogulan extract standardised to (or containing) gypenoside L rather than the pure molecule ^{7,8Reference 7Ahn Y et al. · 2023RCTEffects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: a double-blind, placebo-controlled, randomized trialView study →Reference 8Nayyar D et al. · 2023RCTGynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK in healthy males — randomized human trialView study →}, so no milligram figure for the isolate can be given. The in-vitro anticancer studies used micromolar concentrations applied directly to cells ^{1,2,3Reference 1Ma J et al. · 2019In vitroGypenoside L inhibits proliferation of liver and esophageal cancer cells by inducing senescence — in vitroView study →Reference 2Zheng K et al. · 2016In vitroGypenoside L, isolated from Gynostemma pentaphyllum, induces cytoplasmic vacuolation death in hepatocellular carcinoma cells through reactive-oxygen-species-mediated unfolded protein response — in vitroView study →Reference 3Liao C et al. · 2016In vitroGypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca²⁺ release — in vitroView study →}, which do not translate to an oral human dose, especially given the poor oral bioavailability of this saponin class ^{11Reference 11Wang M et al. · 2020ReviewDammarane-type leads panaxadiol and protopanaxadiol for drug discovery: biological activity and structural modification — reviewView study →}. In practice, any human exposure to gypenoside L comes as one saponin within a jiaogulan preparation, where its individual contribution is unknown. These are doses studied in research and are not a personal recommendation.

References

1. Ma J, Hu X, Liao C, et al. (2019). Gypenoside L inhibits proliferation of liver and esophageal cancer cells by inducing senescence — in vitro. Molecules. https://pubmed.ncbi.nlm.nih.gov/30889805/
2. Zheng K, Liao C, Li Y, et al. (2016). Gypenoside L, isolated from Gynostemma pentaphyllum, induces cytoplasmic vacuolation death in hepatocellular carcinoma cells through reactive-oxygen-species-mediated unfolded protein response — in vitro. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/26870999/
3. Liao C, Zheng K, Li Y, et al. (2016). Gypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca²⁺ release — in vitro. Oncotarget. https://pubmed.ncbi.nlm.nih.gov/27329722/
4. Xiao MY, Pei WJ, Li S, et al. (2024). Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response — in vitro. Bioorganic Chemistry. https://pubmed.ncbi.nlm.nih.gov/38861912/
5. Liu H, Li X, Xie J, et al. (2022). Gypenoside L and gypenoside LI inhibit proliferation in renal cell carcinoma via regulation of the MAPK and arachidonic acid metabolism pathways — in vitro + xenograft. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/35370678/
6. Wang TX, Shi MM, Jiang JG (2018). Bioassay-guided isolation and identification of anticancer and antioxidant compounds from Gynostemma pentaphyllum (Thunb.) Makino — in vitro. RSC Advances. https://pubmed.ncbi.nlm.nih.gov/35540147/
7. Ahn Y, Lee HS, Lee SH, et al. (2023). Effects of gypenoside L-containing Gynostemma pentaphyllum extract on fatigue and physical performance: a double-blind, placebo-controlled, randomized trial. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/36877124/
8. Nayyar D, Yan X, Xu G, et al. (2023). Gynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK in healthy males — randomized human trial. Nutrients. https://pubmed.ncbi.nlm.nih.gov/38004115/
9. Nguyen NH, Ha TKQ, Yang JL, et al. (2021). Triterpenoids from the genus Gynostemma: chemistry and pharmacological activities — review. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/33186700/
10. Razmovski-Naumovski V, Huang THW, Tran VH, et al. (2005). Chemistry and pharmacology of Gynostemma pentaphyllum — review. Phytochemistry Reviews. https://doi.org/10.1007/s11101-005-3754-4
11. Wang M, Li H, Liu W, et al. (2020). Dammarane-type leads panaxadiol and protopanaxadiol for drug discovery: biological activity and structural modification — review. European Journal of Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/32007667/
12. Zhang L, Lin Y, Guan H, et al. (2015). Simultaneous determination of gypenoside LVI, gypenoside XLVI, 2α-OH-protopanaxadiol and their two metabolites in rat plasma by LC-MS/MS and its application to pharmacokinetic studies — rat. Journal of Chromatography B. https://pubmed.ncbi.nlm.nih.gov/26454343/
13. Chen JC, Tsai CC, Chen LD, et al. (2000). Therapeutic effect of gypenoside on chronic liver injury and fibrosis induced by CCl₄ in rats — animal model. The American Journal of Chinese Medicine. https://pubmed.ncbi.nlm.nih.gov/10999436/
14. Takemoto T, Arihara S, Nakajima T, Okuhira M (1983). Studies on the constituents of Gynostemma pentaphyllum Makino. I. Structures of gypenoside I–XIV. Yakugaku Zasshi. https://doi.org/10.1248/yakushi1947.103.2_173

View all 14 references▾